• CONCLUSION: Ex-PRESS P200 glaucoma shunt implantation may be an effective procedure for medically uncontrolled glaucoma with significantly lower use of antiglaucomatous medications.
INTRODUCTION
G laucoma is a progressive optic neuropathy, and intraocular pressure (IOP) is the only known modifiable risk factor. According to the World Health Organization's (WHO) report, the number of persons estimated to be blind Int J Ophthalmol, Vol. 12, No. 8, Aug. 18, 2019 www.ijo.cn Tel: 8629-82245172 8629-82210956 Email: ijopress@163.com under a scleral flap is recommended to limit excessive aqueous flow and to decrease postoperative complications of subconjunctival implantation such as hypotonia and conjunctival erosion [5] . Compared with trabeculectomy, the Ex- In this retrospective study, we wanted to report our experience with Ex-PRESS shunt implantation, the efficacy and safety of the device, the success and complication rates in patients with different types of glaucoma. Figure 3 ).
SUBJECTS AND METHODS

Ethical Approval
The reduction in anti-glaucomatous medication after the surgery was significant. Twenty-nine (93.5%) of 31 patients were using 4, 1 patient (3.2%) was using 2, and 1 patient (3.2%) was using 3 anti-glaucomatous medications before surgery. The patients who were using 2 and 3 medications before surgery were allergic to other anti-glaucomatous drugs.
At the last visit, 13 (41.9%) of 31 patients were not using any anti-glaucomatous medications. At the last visit, the mean number of medications per patient was reduced from a preoperative value of 3.9±0.4 to 1.7±1.7 (P<0.05; Figure 4 ).
At the last visit, the complete success rate was 32.3%, and the qualified success rate was 77.5% in all patients. Failure occurred in 7 (22.6%) patients ( Table 2) . th month in 1 patient, and corneal opacification in 1 patient, in whom early corneal edema was seen (Table 3, Figure 5 ).
Twelve additional surgical treatments were needed and 4 of these were Phaco-IOL surgery alone. Additionally, to this surgical treatments 3 eyes had bleb needling to control high IOP. One of the patients who needed bleb needling had UG and required needling at the 19 th month, the second patient had NVG and required needling at the 17 th month, the third patient had POAG and required needling at the 2 nd month. Fibrotic membranes over tubes were removed in 2 eyes with additional surgery. One of these patients had PKG and blockage occurred at the 6 th month, the other patient had ARS and tube blockage occurred at the 6 th day. Bleb revisions were performed in 3 eyes and 5-FU was used in 2 of these eyes. One of these patients had PXFG and required revision at the 1 st month.
The second patient had POAG and needling was performed, which required revision at the 12 th month. The third patient, in whom fibrotic membranes had previously been removed, had PKG and required revision at the 24 th month. Ex-Press implant was removed from 1 patient at the 6 th month because of endophthalmitis and Phaco-IOL surgery was performed.
Phaco-IOL surgery was performed in another 4 patients. PK was performed in 1 patient at the 18 th month because of corneal opacification. Because of grefon failure in 1 patient in whom fibrotic membrane removal and revision had been performed previously, rekeratoplasty was performed at 8 th month (Table 4) .
When we compared patients with POAG and others within the two groups, complete success rates were 46.7% in POAG group and 18.8% in the others group. The qualified success rates were 90% in the POAG group and 75% in other groups. Table 5 ).
DISCUSSION
Since 1968, the most widely used procedure for glaucoma 
Intraocular hemorrhage, hyphema, iris touch, and choroidal effusion surgery has been trabeculectomy [2] . Trabeculectomy is an effective surgery for controlling medically uncontrolled glaucoma but has severe complications. The potential complications of trabeculectomy include early hypotony, choroidal detachment, and bleb-related problems [3] . In recent years, there has been increasing interest in finding an alternative to trabeculectomy in glaucoma surgery, which explains the rising popularity of this field in ophthalmic surgery. The Ex-PRESS glaucoma shunt device was created to mimic the effect of trabeculectomy and improve its safety.
Compared with trabeculectomy, the Ex-PRESS device
eliminates the need for both peripheral iridectomy and removal of a deep corneoscleral tissue block. The initial tube was designed for subconjunctival implantation. Complications such as conjunctival erosion, tube obstruction, and device dislocation were seen with this technique [6] . In 2005, Dahan and Carmichael described an alternative surgical technique in which a device was implanted under a scleral flap [5] .
Maris et al [7] reported satisfactory IOP control and reduced postoperative complication rates with this new technique.
The Ex-PRESS shunt device has been in widespread use but there is a paucity of data regarding its results. In this retrospective study, we investigated the efficacy and safety of the Ex-PRESS P200 device in a group of patients with different types of medically uncontrolled glaucoma.
In our study, the mean IOP reduction was 39.9%±30.6%
when comparing the last visit with pre-operative values in all patients. Our results for all patients are similar to other studies in the literature. Dahan and Carmichael reported >35% mean IOP reduction at all time points in 24 eyes after implantation of Ex-PRESS devices under scleral flaps [5] . De Jong et al [8] reported 42%, and Good and Kahook [9] reported a 45% mean IOP reduction. In the others group, the mean IOP reduction was -51.91±26.43 mm Hg, greater than the POAG group's reduction, which was -27.10±30.41 mm Hg. We think that the reason for this was the higher baseline IOP values of the others group. The final IOP values were similar between the two groups.
In 7 patients vision worsened: >2 Snellen lines but 6 patients gained a significant amount of vision: >2 Snellen lines Same patient. Wilcoxon signed-rank test. In our study, the most common early complication was leakage, which was seen in 7 patients (22.6%). In Dahan et al's [10] study, the bleb leakage ratio was 7%, in de Jong's [11] study it was 2.5%, in Netland et al's [12] study, the early wound leak ratio was 3.3% and late bleb leakage ratio was 1.7%, and it was 6% in the device group in Maris et al's [7] study. Only in
Ex-PRESS implantation for complicated cases
Marzette and Herndon's [13] study was the bleb leakage ratio higher than in our study (29%).
Choroidal hemorrhage, hyphema, and choroidal effusion were seen in 1 patient. Choroidal effusion was reported in 8% of cases in Maris et al's [7] study, 4% in Marzette and Herndons [13] study, and 6.8% in Netland et al's [12] study. Choroidal detachment was reported in 20% of cases in Sugiyama et al's [14] study, and 7.5% in de Jong's [11] study. In Wang et al's [15] study, choroidal effusion was reported in 4.2% of cases in the Ex-PRESS group and 29.2% in the trabeculectomy group.
Corneal edema was seen in 1 patient on the first day after surgery, and corneal opacification was seen in the same patient at 18mo. In this study endothelial cell counting was not a routine procedure so we cannot comment as to whether it was because of surgery or endothelial cell insufficiency. Implantation surgery is considered to be a safer procedure but it can cause more corneal complications than trabeculectomy [16] [17] . Lee et al [18] reported statistically significant differences between trabeculectomy and Ex-PRESS shunt implantation, particularly in IOP fluctuation and the rate of endothelial cell loss. In their analysis, endothelial cell loss was significantly higher in the trabeculectomy group [18] . The mechanism underlying the damage to corneal endothelial cells following Ex-PRESS implantation remains unknown. There
are as yet no long-term follow-up reports on the safety of ExPress implantation in the corneal endothelium.
Twelve additive surgical interventions and 3 bleb needling procedures were performed. The bleb needling ratio was similar to other studies in the literature. In the study of Maris et al [7] , the bleb needling with 5-FU ratio was 20% in the device group, and in Sugiyama and Gallego-Pinazo's study the bleb needling ratios were also 20% in the device group [14, 19] .
The Ex-PRESS implant was removed at the 6 th month in 1 patient because of endophthalmitis. In Maris et al's [7] study, endophthalmitis was reported at a rate of 2% in the device group. In our study, medical and surgical interventions were performed more than in other studies because our study included complicated glaucoma cases. In our study, number of phakic patients was 15, 4 of whom needed cataract extraction surgery after Ex-PRESS implantation. In a recent randomized clinical trial for postoperative complications after Ex-PRESS implantation versus trabeculectomy, Arimura et al [20] reported that although Ex-PRESS implantation might be associated with an increased rate of corneal endothelial cell loss compared with trabeculectomy, it is beneficial for preventing cataract progression. The reason for cataract progression after glaucoma surgery is not clearly understood.
Our study included 1 patient with NVG. We observed no early or late complications in this patient. This patient required bleb needling at the 17 th month and qualified success was observed at the end of the follow-up even though this was a complicated glaucoma case. In a recent retrospective comparative study with 1-year follow-up, Ex-PRESS shunt surgery was found less effective but safer than trabeculectomy for the treatment of patients with NVG [21] .
In the literature, complete and qualified success criteria differ between studies. In our study, complete success was defined as IOP≥5 and ≤21 mm Hg without medication, and qualified success was defined as IOP≥5 and ≤21 mm Hg with medication. Our complete success rate was 32.3% at the last visit, and the qualified success rate was 77.5% at the last visit. Bissig et al. reported the complete success rate as 69% and the qualified success rate as 85% (IOP>6 and ≤18 mm Hg) at the last follow-up [22] . Gindroz et al [23] found the complete success rate as 46% and the qualified success rate was 85% at 48mo. In the study of Kanner et al [24] , the qualified success rate was 95% at 3y (IOP≥5 and ≤21 mm Hg) in the non-cataractous group and 96% in the cataractous group. Lankaranian et al [25] reported the complete success rate as 80% at 1y, 64% at 2y, and 56% at 3y, and the qualified success rate was 94% at 1y, 77.5% at 2y, and 67% at 3y (IOP≥5, ≤21 mm Hg). In our study, when we compared the POAG and others groups, the complete success rate was 46.7%; the qualified success rate was 90% in the POAG group and the complete success rate was 18.8%; and the qualified success rate was 75% in the others group. When compared with other studies, our success rates were lower in the others group, which included patients with complicated glaucoma, but similar in the POAG group.
In our study, there was a significant reduction in the number of glaucoma medications after implantation of Ex-Press devices. The mean number of medications at the start was 3.9±0.4, which lowered to a mean of 1.7±1.7 (P<0.05) at the last visit. Coupin et al [26] indicated that the number of topical medications went from a mean of 1.9±1.0 down to 1±1.0 after surgery. Maris et al. reported an important reduction went from 3.7±0.9 to 0.7±1.2, similar to Couplin et al's [26] report.
Lee et al [18] showed a significant reduction from 2.75±0.45
to 0.53±0.80 over a 12-month evaluation period in the Ex-PRESS group. We think that the final number of medications was higher in our study than in other studies because of group heterogeneity and the long duration of follow-up.
In conclusion, although this study included complicated glaucoma cases, IOP and anti-glaucoma medications were significantly reduced at the last visit. Overall, the complication rate was high. The major limitation of our study is its small sample size (31 eyes), the retrospective design of the study, and lack of anti-fibrotics. Studies including a larger number of complicated glaucoma cases with long-term follow-up will provide further information on the efficacy and safety of Ex-PRESS implantation.
